Takeaways presented in poster at Keystone conference, Obesity Therapeutics: Unlocking Benefits and Minimizing Side Effects:
•Nimacimab significantly enhanced weight loss when combined with suboptimal or clinically active dose levels of tirzepatide.
•Nimacimab resulted in durable weight loss after treatment discontinuation.
•Nimacimab significantly improved rebound profile after tirzepatide discontinuation.
•Caloric restriction is not the primary driver of nimacimab-driven weight loss.
•An active vs a suboptimal dose of nimacimab significantly enhanced weight loss induced by semaglutide.
